Original Paper

2 downloads 0 Views 359KB Size Report
Kakafika, Anna; Aristotle University of Thessaloniki, Hippocration ... 1Vassilios G. Athyros, 2Emmanouel Ganotakis, 3Genovefa Kolovou, 4Vassilios Nicolaou, ...
Current Vascular Pharmacology

Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT). A prospectiverandomized study in middle aged men and women. List of Authors Athyros, Vasilios G.; Aristotle University of Thessaloniki, Hippocration Hospital, Internal Medicine Ganotakis, Emmanuel; University of Crete, Internal Medicine Kolovou, Genovefa; Onasis Center, Cardiology Clinic Nikolaou, Vasilios; Red Cross Hospital, Cardiology Achimastos, Apostolos; University of Athens, Internal Medicine Bilianou, Eleni; Tzanio Hospital, Cardiology Alexandrides, Theodore; University of Patras, Internal Medicine Endocrinology Karagiannis, Asterios; Aristotle University of Thessaloniki, Hippocration Hospital, Internal Medicine Paletas, Konstantinos; Aristotle University of Thessaloniki, Hippocration Hospital, Internal Medicine Liberopoulos, Vagelis; School of Medicine, University of Ioannina, Internal Medicine Tziomalos, Konstantinos; Aristotle University of Thessaloniki, AHEPA Hospital, Internal Medicine Petridis, Dimitrios; Ehinos Health Center, General Medicine Kakafika, Anna; Aristotle University of Thessaloniki, Hippocration Hospital, Internal Medicine Elisaf, Moses; School of Medicine, University of Ioannina, Internal Medicine Mikhailidis, Dimitri P; Royal Free Campus, University College

1

Original Paper

Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT). A prospective-randomized study in middle aged men and women.

Running head: CVD risk in metabolic syndrome after multifactorial treatment 1

Vassilios G. Athyros, 2Emmanouel Ganotakis, 3Genovefa Kolovou, 4Vassilios Nicolaou, 5Apostolos

Achimastos, 6Eleni Bilianou, 7Theodore Alexandrides, 1Asterios Karagiannis, 1Konstantinos Paletas, 8

Eyangelos N. Liberopoulos, 1Konstantinos Tziomalos, 9Dimitrios Petridis, 1Anna Kakafika, 8oses S. Elisaf,

10

Dimitri P. Mikhailidis; for the Assessing The Treatment Effect in Metabolic Syndrome Without

Perceptible diabeTes (ATTEMPT) Collaborative*. *23 co-investigators are listed in the acknowledgement section 1Second

Propedeutic Department of Internal Medicine, Medical School, Aristotle University of

Thessaloniki, Thessaloniki, Greece, 2Department of Internal Medicine, Medical School, University of Crete, Heraklion, Greece, 3Cardiology Department, Onassis Cardiac Surgery Center, Athens, Greece, 4First Cardiology Department, Red Cross Hospital, Athens, Greece, 5Third Department of Medicine, University of Athens, Medical School, Sotiria General Hospital, Athens, Greece, 6Cardiology Department, Tzanio State Hospital, Piraeus, Greece, Division of Endocrinology, Department of Internal Medicine, University of Patras, Medical School, Rio Hospital, Patras Greece, 9Department of Internal Medicine, Medical School, University of Ioannina, Greece,

10Department

of Clinical Biochemistry, Royal Free Campus, University

College London Medical School, University College London, UK.

CORRESPONDENCE:

D P Mikhailidis, BSc MSc MD FRSPH FCP FFPM FRCP FRCPath Academic Head, Department of Clinical Biochemistry Royal Free Hospital Campus, University College London Medical School, University College London (UCL), Pond Street, London NW3 2QG, UK Tel: +44 20 7830 2258, Fax: +44 20 7830 2235, e-mail: [email protected]

2

ABSTRACT Aim-To assess the reduction in estimated cardiovascular disease (e-CVD) risk after multifactorial treatment for 6 months and follow this change during the next 3-years. Patients-Methods-This prospective, randomized, target driven study included 1,123 subjects (512/611 men/women, aged 45-65 years) with metabolic syndrome (MetS) without diabetes or CVD referred to specialist outpatient clinics. Patients were randomized to two treatment groups: group A with low density lipoprotein cholesterol (LDL-C) target of 60% even in non-diabetic patients free of cardiovascular disease at baseline. 2. Attainment of LDL-C target 102 cm for men or >88 cm for women; TG levels >150 mg/dl (1.7 mmol/l); HDL-C levels 100 mg/dl (5.6 mmol/l). Exclusion criteria in our study were: TG levels >500 mg/dl (5.6 mmol/l), pregnancy or lactation, hormone replacement therapy, active hepatic disease (known hepatitis or unexplained persistent transaminases elevation >100 IU/l), secondary or resistant arterial hypertension, advanced renal disease (estimated glomerular filtration rate